Holen Sie sich die Stockscreener-App
5.69
2.23%
-0.13
Handel nachbörslich:
5.69
Schlusskurs vom Vortag:
$5.82
Offen:
$5.73
24-Stunden-Volumen:
880.51K
Relative Volume:
0.70
Marktkapitalisierung:
$492.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-2.6221
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+0.89%
1M Leistung:
-12.73%
6M Leistung:
-48.46%
1J Leistung:
-72.50%
1-Tages-Spanne:
$5.53
$5.74
1-Wochen-Bereich:
$5.48
$5.84
52-Wochen-Spanne:
$5.41
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
5.69 | 488.28M | 0 | -168.09M | -138.01M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Buys 21,135 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Kura Oncology’s SWOT analysis: ziftomenib success key to stock’s future By Investing.com - Investing.com South Africa
Kura Oncology’s SWOT analysis: ziftomenib success key to stock’s future - Investing.com
Kura Oncology (NASDAQ:KURA) Trading Down 4.7% – Time to Sell? - Defense World
Cantor Fitzgerald maintains Overweight on Kura Oncology stock - Investing.com Australia
Cantor Fitzgerald maintains Overweight on Kura Oncology stock By Investing.com - Investing.com South Africa
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - MSN
Jane Street Group LLC Sells 25,869 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology to present trial results for AML treatment - Investing.com Australia
Kura Oncology to present trial results for AML treatment By Investing.com - Investing.com Nigeria
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Announce KOMET-001 Trial Results for Ziftomenib in R/R NPM1-m AML Selected for ASCO Presentation - Nasdaq
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting - The Manila Times
Northern Trust Corp Sells 20,239 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology to Participate in Three Upcoming Investor Conferen - GuruFocus
Kura Oncology to Participate in Three Upcoming Investor Conferences - The Manila Times
Kura Oncology, Inc. to Participate in Upcoming Investor Conferences in May and June 2025 - Nasdaq
Kura Oncology Sets Triple Conference Schedule: Goldman Sachs, Jefferies, and TD Cowen Healthcare Events - Stock Titan
Kura Oncology (NASDAQ:KURA) Price Target Lowered to $30.00 at Mizuho - Defense World
KURA: Mizuho Maintains Rating but Lowers Price Target for Kura O - GuruFocus
Kura Oncology (KURA) Target Price Adjusted by Mizuho | KURA Stoc - GuruFocus
Balyasny Asset Management L.P. Has $144,000 Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Stock Position Raised by BNP Paribas Financial Markets - Defense World
Price T Rowe Associates Inc. MD Raises Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Mizuho Adjusts Price Target on Kura Oncology to $30 From $32, Maintains Outperform Rating - marketscreener.com
How To Trade (KURA) - news.stocktradersdaily.com
Kura Oncology (KURA) to Present Promising AML Treatment Data at 2025 EHA Congress | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Announce Combination Data for Zift - GuruFocus
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress - The Manila Times
Kura Oncology and Kyowa Kirin to Present Updated Data on Ziftomenib in Combination with 7+3 for AML at EHA2025 Congress - Nasdaq
Kura Oncology Inc (NASDAQ: KURA) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister
Kura Oncology’s Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks
Voya Investment Management LLC Decreases Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Transcript : Kura Oncology, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Dimensional Fund Advisors LP Buys 372,196 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates - simplywall.st
Wells Fargo & Company MN Acquires 11,427 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Canada
MetLife Investment Management LLC Purchases 2,776 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com Australia
Kura Oncology to Participate in Bank of America Securities Healt - GuruFocus
KURA Stock Set for Competitive Landscape in Menin Inhibitor Mark - GuruFocus
Kura Oncology to Participate in Bank of America Securities Healthcare Conference - The Manila Times
Kura Oncology CEO Sets Stage for Major Updates at BofA Healthcare Conference Next Week - Stock Titan
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):